Evaluation of an electronic diary for improvement of adherence to interferon beta-1b in patients with multiple sclerosis: design and baseline results of an observational cohort study

被引:16
|
作者
Zettl, Uwe K. [1 ]
Bauer-Steinhusen, Ulrike [2 ]
Glaser, Thomas [2 ]
Hechenbichler, Klaus [3 ]
Limmroth, Volker [4 ]
机构
[1] Univ Med Rostock, Klin & Poliklin Neurol, Rostock, Germany
[2] Bayer Vital GmbH, Immunol & Ophthalmol, Med Neurol, Leverkusen, Germany
[3] Inst Dr Schauerte, Oberhaching, Germany
[4] Stadt Klinikum Koln Merheim, Klin Neurol, Cologne, Germany
来源
BMC NEUROLOGY | 2013年 / 13卷
关键词
Adherence; Interferon beta-1b; Non-interventional study; Electronic diary; Multiple sclerosis; Immunomodulation; DEPRESSIVE SYMPTOMS; CES-D; THERAPY; POPULATION; VALIDATION; MEDICATION; IMPACT; COSTS; DRUGS; CARE;
D O I
10.1186/1471-2377-13-117
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Multiple sclerosis is a chronic, incurable, demyelinating disease that requires long-term treatment. Rates of non-adherence to prescribed therapy of up to 50% have been reported for chronic diseases. Strategies to improve treatment adherence are therefore of the utmost importance. This study will evaluate the effect of using electronic and paper diaries on treatment adherence to interferon beta-1b in patients with a first clinical isolated syndrome (CIS) or relapsing-remitting multiple sclerosis (RRMS). Here we report on the study design and results of baseline assessments. Methods: Patients were recruited into a prospective national multicenter cohort study for an observational period of 2 years. At the start of the study, patients opted to use a digital (DiD) or paper diary (PD) to document self-administered injections of interferon beta-1b. Adherence to treatment will be assessed on the dropout rate at the end of the observation period and on the regularity of injections every other day at 6-month intervals. Patient-related health outcomes will also be evaluated. Results: 700 patients with a mean age of 38.3 (SD 10.3) years and a mean duration of disease since diagnosis of 3.6 (SD 5.9) years were enrolled. 383 patients opted for the digital diary, 192 of which included an injection reminder. Significantly more male than female patients opted for the DiD. Only gender was identified as a factor influencing the decision for DiD or PD. Based on rating scales, a significantly higher proportion of women had depressive comorbidities at baseline. Conclusions: Demographic characteristics of the two cohorts were similar at baseline. More women chose a paper diary, and more had depression at baseline. These imbalances will be addressed in the analysis of the study as possible confounders influencing long-term treatment adherence in the digital and paper diary cohorts.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis
    Jankovic, Slobodan M.
    JOURNAL OF INFLAMMATION RESEARCH, 2010, 3 : 25 - 31
  • [32] Evaluation of interferon beta-1b therapy effects on the level and abnormal nature of immunoglobulin G in patients with multiple sclerosis
    Hychka, K. M.
    Boichuk, M. O.
    Dumych, T., I
    Paryzhak, S. Ya
    Bilyi, R. O.
    Nehrych, T., I
    ZAPOROZHYE MEDICAL JOURNAL, 2018, (06) : 762 - 767
  • [33] Effects of dose titration on tolerability and efficacy of interferon beta-1b in people with multiple sclerosis
    Wroe, SJ
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2005, 33 (03) : 309 - 318
  • [34] Meningioma growth and interferon beta-1b treated multiple sclerosis: coincidence or relationship?
    Drevelegas, A
    Xinou, E
    Karacostas, D
    Parissis, D
    Karkavelas, G
    Milonas, I
    NEURORADIOLOGY, 2005, 47 (07) : 516 - 519
  • [35] Long-term experience with interferon beta-1b (Betaferon®) in multiple sclerosis
    Arnason, BGW
    JOURNAL OF NEUROLOGY, 2005, 252 (Suppl 3) : 28 - 33
  • [36] Meningioma growth and interferon beta-1b treated multiple sclerosis: coincidence or relationship?
    A. Drevelegas
    E. Xinou
    D. Karacostas
    D. Parissis
    G. Karkavelas
    I. Milonas
    Neuroradiology, 2005, 47 : 516 - 519
  • [37] PERSISTENCE ON INTERFERON Beta-1b IN MULTIPLE SCLEROSIS: 19-YEAR OF FOLLOW-UP
    Sirbu, Carmen Adella
    Plesa, Cristina Florentina
    Ghinescu, Minerva Claudia
    Caloianu, Ionut
    Ionita-Radu, Florentina
    FARMACIA, 2020, 68 (04) : 752 - 756
  • [38] Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis
    Richert, ND
    Ostuni, JL
    Bash, CN
    Leist, TP
    McFarland, HF
    Frank, JA
    MULTIPLE SCLEROSIS, 2001, 7 (01): : 49 - 58
  • [39] Thrombotic microangiopathy caused by interferon beta-1b for multiple sclerosis: a case report
    Nishio, Haruomi
    Tsukamoto, Tatsuo
    Matsubara, Takeshi
    Okada, Yoichiro
    Takahashi, Ryosuke
    Yanagita, Motoko
    CEN CASE REPORTS, 2016, 5 (02): : 179 - 183
  • [40] Long-term experience with interferon beta-1b (Betaferon®) in multiple sclerosis
    Barry G. W. Arnason
    Journal of Neurology, 2005, 252 : iii28 - iii33